Skip to main content
. 2014 Sep 4;111(38):13870–13875. doi: 10.1073/pnas.1414358111

Fig. 5.

Fig. 5.

Inhibition of p38 suppresses BCa metastasis. C57BL/6 females were injected with PyMT (Py8119) cells via the tail vein and treated with the p38 inhibitor SB203580 (15 mg/kg body weight) or vehicle control by daily oral gavage for 4 wk. Lung metastases were quantified by surface nodule numbers (A). Representative lung images are shown in B. (Scale bar, 1 cm.) In another set of experiments, daily p38 inhibitor administration was initiated on either day 0 or 2 wk after BCa cell implantation (C). Lung metastases under both treatment regimens (4 and 2 wk) were quantified and compared by counting surface nodules (D). Results in A and D are averages ± SEM; n = 4–5 mice in each group. (E and F) Correlation between expression of p38 (MAPK14) and Ubc13 and breast cancer patient survival. Kaplan–Meier survival curves for samples classified as indicated. Shown are overall survival percentages for MAPK14 (tertiles) (E) and Ubc13 (quartiles) (F) expression based on clinical information available in the TCGA for the BRCA dataset. **P = 0.0023, *P = 0.0369.